E2SMed

E2SMed is a South Korean biotechnology company specializing in the development of first-in-class small molecule therapeutics for metabolic diseases, including Metabolic dysfunction-associated steatohepatitis (MASH) and obesity. The company's core technology focuses on liver-targeted mitochondrial uncoupling, a mechanism designed to increase energy expenditure and reduce fat accumulation without systemic side effects. Its lead candidate, ES-101, is currently in pre-clinical development for MASH, demonstrating promising results in reducing liver fat and fibrosis in animal models. E2SMed aims to address the global epidemic of metabolic disorders through its innovative approach to mitochondrial modulation and metabolic regulation. The company is supported by prominent South Korean venture capital firms and is actively advancing its pipeline toward clinical trials.